IN2015DN02573A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02573A
IN2015DN02573A IN2573DEN2015A IN2015DN02573A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A IN 2573DEN2015 A IN2573DEN2015 A IN 2573DEN2015A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A
Authority
IN
India
Prior art keywords
pulmonary fibrosis
compound
present
formula
idiopathic
Prior art date
Application number
Other languages
English (en)
Inventor
Ulf; Nilsson
Hakon; Leffler
Neil; Henderson
Tariq; Sethi
Alison; Mackinnon
Original Assignee
Galecto Biotech Ab
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by Galecto Biotech Ab, Univ Edinburgh filed Critical Galecto Biotech Ab
Publication of IN2015DN02573A publication Critical patent/IN2015DN02573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IN2573DEN2015 2012-10-31 2013-10-30 IN2015DN02573A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
IN2015DN02573A true IN2015DN02573A (cg-RX-API-DMAC7.html) 2015-09-11

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2573DEN2015 IN2015DN02573A (cg-RX-API-DMAC7.html) 2012-10-31 2013-10-30

Country Status (7)

Country Link
EP (2) EP2914269B1 (cg-RX-API-DMAC7.html)
JP (1) JP2015535233A (cg-RX-API-DMAC7.html)
CN (1) CN104755088A (cg-RX-API-DMAC7.html)
CA (1) CA2884802A1 (cg-RX-API-DMAC7.html)
ES (1) ES2817888T3 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02573A (cg-RX-API-DMAC7.html)
WO (1) WO2014067986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
EP3415522A1 (en) 2014-07-09 2018-12-19 Galecto Biotech AB Novel hybrid galactoside inhibitor of galectins
EP3245216B1 (en) 2015-01-16 2019-12-11 Galecto Biotech AB Novel galactoside inhibitor of galectins
US10774102B2 (en) * 2015-01-30 2020-09-15 Galecto Biotech Ab Galactoside inhibitor of galectins
WO2016180483A1 (en) * 2015-05-12 2016-11-17 Galecto Biotech Ab Once-daily treatment of pulmonary fibrosis
JP6915956B2 (ja) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ 肺線維症の１日１回の治療
WO2017019770A1 (en) * 2015-07-27 2017-02-02 Wayne State University Compositions and methods relating to galectin detection
JP6892859B2 (ja) * 2015-11-09 2021-06-23 ガレクト・バイオテック・エイビイ 新規ガラクトシドによるガレクチン阻害剤
EP3390423B1 (en) 2015-12-18 2022-08-03 Galecto Biotech AB Polymorphic forms and process
KR102346913B1 (ko) * 2016-03-04 2022-01-04 갈랙틴 사이언시즈, 엘엘씨 갈렉틴과 관련된 질환의 예방 및 치료를 위한 셀레노갈락토시드 화합물 및 이의 용도
JP7038099B2 (ja) * 2016-07-12 2022-03-17 ガレクト バイオテック エービー ガレクチンのα－Ｄ－ガラクトシド阻害剤
WO2018011094A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
JP7204676B2 (ja) 2017-05-12 2023-01-16 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー 疾患の予防および治療用の化合物およびその使用
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3
US11072626B2 (en) 2017-10-11 2021-07-27 Bristol-Myers Squibb Company Small molecule inhibitors of Galectin-3
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
MX2020007391A (es) 2018-01-10 2020-09-03 Galecto Biotech Ab Nuevo galactosido inhibidor de galectinas.
US12083098B2 (en) 2018-05-17 2024-09-10 Actuate Therapeutics Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors
US11970511B2 (en) 2018-06-15 2024-04-30 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as Galectin-3 inhibitors
CN112672765A (zh) * 2018-06-29 2021-04-16 格莱科斯生物医药公司 结合物
JP2022508719A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤のプロドラッグ
JP2022508720A (ja) 2018-10-15 2022-01-19 ガレクト バイオテック エービー ガレクチンのガラクトシド阻害剤
CN113412267B (zh) 2018-11-21 2025-06-27 格莱克特生物技术公司 半乳糖凝集素的α-D-半乳糖苷抑制剂
KR20210100139A (ko) 2018-12-06 2021-08-13 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3의 소분자 억제제
CN118373810A (zh) 2018-12-27 2024-07-23 糖模拟物有限公司 抑制c-糖苷的半乳凝素-3
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
EP3947407B1 (en) 2019-03-26 2024-06-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
JP7577682B2 (ja) 2019-04-10 2024-11-05 ブリストル－マイヤーズ スクイブ カンパニー ガレクチン－３の低分子阻害剤
US12291547B2 (en) 2019-06-14 2025-05-06 UNIVERSITé LAVAL Synthesis of 3-azido-3-deoxy-D-galactopyranose
EP3986905A1 (en) 2019-06-24 2022-04-27 Galecto Biotech AB Large scale process of 3,3'-dideoxy-3,3'-bis-[4-(3-fluorophenyl)-1h-1,2,3-triazol-1-yl]-1,1'-sulfanediyl-di-beta-d-galactopyranoside
WO2021001528A1 (en) 2019-07-03 2021-01-07 Galecto Biotech Ab Novel galactoside inhibitor of galectins
CN114514235A (zh) 2019-07-03 2022-05-17 格莱克特生物技术公司 半乳糖凝集素的新型半乳糖苷抑制剂
US12441755B2 (en) 2019-07-05 2025-10-14 Galecto Biotech Ab Galactoside inhibitor of galectins
US12404295B2 (en) 2019-08-09 2025-09-02 Idorsia Pharmaceuticals Ltd (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives
WO2021028323A1 (en) 2019-08-09 2021-02-18 Idorsia Pharmaceuticals Ltd (2-acetamidyl)thio-beta-d-galactopyranoside derivatives
KR102832308B1 (ko) 2019-08-15 2025-07-10 이도르시아 파마슈티컬스 리미티드 2-히드록시시클로알칸-1-카르바모일 유도체
MY207787A (en) 2019-08-29 2025-03-19 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
US20230107479A1 (en) * 2020-03-23 2023-04-06 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
US20230137160A1 (en) 2020-03-31 2023-05-04 Galecto Biotech Ab Large scale process for preparing 1,2,4, 6-tetra-o-acetyl-3-azido-3-deoxy-d-galactopyranoside
EP4146646A1 (en) 2020-05-05 2023-03-15 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
EP4149939A1 (en) 2020-05-11 2023-03-22 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
KR20230018431A (ko) 2020-05-28 2023-02-07 브리스톨-마이어스 스큅 컴퍼니 갈렉틴-3 억제제
WO2022073969A1 (en) 2020-10-06 2022-04-14 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
CA3197095A1 (en) 2020-11-02 2022-05-05 Martin Bolli Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives
CN116806219A (zh) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 羟基杂环烷-氨甲酰基衍生物
CN116888113A (zh) 2021-03-03 2023-10-13 爱杜西亚药品有限公司 经三唑基-甲基取代的α-D-吡喃半乳糖苷衍生物
WO2025111704A1 (en) * 2023-12-01 2025-06-05 UNIVERSITé LAVAL Selective inhibitors of galectin-3

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE33447T1 (de) 1984-08-09 1988-04-15 Brugger Inge Zerstaeubervorrichtung.
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
KR100246082B1 (ko) 1991-07-02 2000-04-01 인헤일, 인코오포레이티드 에어로졸화된약제를전달하는방법및장치
ATE209053T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhaliervorrichtung
DE19726110C2 (de) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosolgenerator für Beatmungssysteme
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (de) 2001-01-23 2012-04-12 Pari Pharma Gmbh Aerosolgenerator
EP1304130B1 (de) 2001-10-18 2004-06-23 PARI GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
AU2002343094A1 (en) * 2001-11-26 2003-06-10 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
DE60235883D1 (de) 2002-08-02 2010-05-20 Pari Pharma Gmbh Vorrichtung zur Erzeugung von Flüssigkeitströpfchen
DE10250625A1 (de) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
DE10257381B4 (de) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalationstherapievorrichtung
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
EP1782808A4 (en) * 2004-07-22 2008-12-03 Kaken Pharma Co Ltd MEANS FOR THE PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY LUNG DISEASE
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
DE102009026636B4 (de) 2009-06-02 2011-04-14 Pari Pharma Gmbh Verfahren zum Verschweißen einer Membran mit einem Träger bei der Herstellung eines Membranverneblers
CN111110850A (zh) * 2011-04-12 2020-05-08 莫伊莱麦屈克斯公司 用于预防或治疗以成纤维细胞异常增殖及细胞外基质沉积为特征的疾病的组合物和方法

Also Published As

Publication number Publication date
EP2914269B1 (en) 2020-07-29
EP2914269A1 (en) 2015-09-09
WO2014067986A1 (en) 2014-05-08
ES2817888T3 (es) 2021-04-08
WO2014067986A8 (en) 2016-04-14
EP3278805A1 (en) 2018-02-07
JP2015535233A (ja) 2015-12-10
CA2884802A1 (en) 2014-05-08
CN104755088A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
IN2015DN02573A (cg-RX-API-DMAC7.html)
NZ708501A (en) Treatment of pulmonary disease
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
MX368263B (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica.
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
MX375872B (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas.
MX2015008187A (es) Inhibidores de alk deuterados.
TN2014000095A1 (en) Pharmaceutical compositions
MX2015007916A (es) Peri-carbinoles.
PH12014500990A1 (en) Methods for treating gout flares
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX347541B (es) Analogos de acido sialico.
PH12014502065A1 (en) Vesicular formulations
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
TN2014000227A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
TN2013000023A1 (en) Panthenyl docosahexaeneoate and its use for treating and preventing cardiovascular diseases